Story perspectives

Promising Acne Treatment Denifanstat Shines in Phase 3 Trials

9/18/2025

26 4

Summary

Story summary

Sagimet Biosciences announced positive Phase 3 trial results for denifanstat in treating moderate to severe acne.
The trial, involving 480 patients in China over 12 weeks, showed significant improvements in treatment success and lesion reduction, with good tolerability.
Denifanstat met all primary and secondary endpoints, suggesting its potential as a new acne treatment.
Sagimet is also developing another FASN inhibitor, TVB-3567, for acne.
The findings were presented at the EADV Congress 2025 in Paris, addressing the needs of over 50 million acne-affected individuals in the U.S.

1 of 1

Story summary

Sagimet Biosciences announced positive Phase 3 trial results for denifanstat in treating moderate to severe acne.
The trial, involving 480 patients in China over 12 weeks, showed significant improvements in treatment success and lesion reduction, with good tolerability.
Denifanstat met all primary and secondary endpoints, suggesting its potential as a new acne treatment.
Sagimet is also developing another FASN inhibitor, TVB-3567, for acne.
The findings were presented at the EADV Congress 2025 in Paris, addressing the needs of over 50 million acne-affected individuals in the U.S.